TNFSF13B and systemic lupus erythematosus: Belimumab is a human anti-BlyS monoclonal antibody (administered intravenously or subcutaneously) that was approved in 2011 in the US and Europe for the treatment of adult SLE and in 2019 for the intravenous treatment of pediatric lupus patients (ages 5–17).